Wyss Institute spinout looks to revamp drug development for CNS diseases — with CRISPR tadpoles
For Rett syndrome, like other neurological diseases, drug development has largely been a story of failure.
To Richard Novak, a former lead engineer at the Wyss Institute, a big part of that is that the traditional drug development paradigm — identifying targets, finding drugs that impact those targets and then putting the drugs in preclinical models before finally testing them in humans — doesn’t really work. So Novak and another Wyss Institute scientist, Frederic Vigneault, are pushing a new platform that goes against the target-first model — and it uses tadpoles.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.